Supernus To Present At Piper Jaffray Healthcare Conference In December

ROCKVILLE, Md., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the Piper Jaffray Healthcare Investor Conference.
Presentation Date: Wednesday, December 4 
Time: 3:00pm ET
Place:  The New York Palace, New York, NY

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR TM (extended release oxcarbazepine), and Trokendi XR TM (extended release topiramate).   The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO         Gregory S. Patrick, Vice President and CFO         Supernus Pharmaceuticals, Inc.         Tel: (301) 838-2591

If you liked this article you might like

More Tax Reform Winners

More Tax Reform Winners

CVS Health, Coca-Cola, Norfolk Southern: 'Mad Money' Lightning Round

CVS Health, Coca-Cola, Norfolk Southern: 'Mad Money' Lightning Round

Victory Comes From Leadership: Cramer's 'Mad Money' Recap (Thursday 11/9/17)

Victory Comes From Leadership: Cramer's 'Mad Money' Recap (Thursday 11/9/17)

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round